fda compounding semaglutide warning letters november 2025 issued 25 to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of From Crackdown to Collaboration: FDA

The FDA's Category 2 designation means the substance may present significant safety risks when used in compounding and is prohibited in compounded medications pending further evaluation

Glossary Triple Agonist A compound that simultaneously activates three distinct receptor types

While a direct causal link was not publicly established, this episode is a sobering reminder that early tolerability data in small studies do not guarantee safety at scale or over time

Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level

Thus, the mode of action of a given GLP-1RA may be highly dependent on its individual pharmacokinetic properties

And we are going to discuss assessment and testing in great detail in Part 2